Why is it so difficult to publish negative results?
DOI:
https://doi.org/10.19230//jonnpr.2363Keywords:
-Abstract
-Downloads
References
Stephens J. Where profits and lives hang in Balance. The Body Hunters. The Washington Post, Dec 17, 2000.
Stephens J. Panel Faults Pfizer in ’96 Clinical Trial in Nigeria. The Washington Post, May 7 2006.
Stephens J. Pfizer to Pay $75 Million to Settle Nigerian Trovan Drug- Testing Suit. The Washington Post. July 31, 2009.
Laporte JR. Las supuestas ventajas de celecoxib y rofecoxib: fraude científico. Butlletí groc. Julio-Septiembre 2002; 15 (Nº4): 13-15
Bruckner T, Ellis B. Clinical Trial Transparency: A Key to Better and Safer Medicines. Working Paper. April 2017. DOI: 10.13140/RG.2.2.21249.35686
Hampton J. Therapeutic fashion and publication bias: the case of anti- arrhythmic drugs in heart attack. JLL Bulletin: Commentaries on the story of treatment evaluation. 2015.
Ioanidis J. Why most clinical research is not useful. PloSMed 13(6):e1002049. Doi:10.1371/journal.pmed.1002049. June 21,2016.
Courtney D et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study fo drug appovals 2009-13. BMJ 2017;
:j4530 doi:10.1136/bmj.j4530
Angells M. The truth about the drug companies: how they deceive us and what to do about it. New York. Random House. 2004.
EFPIA. The pharmaceutical industry in figures. Key data 2017.
Baker D. Bird Flu Fears: Is there a better way to develop drugs? CEPR Issue brief. October 2005.
Lamata F, Gálvez R, Sánchez-Caro J, Pita Barros P, Puigventós F. Medicamentos: ¿derecho humano o negocio? Díaz de Santos. Madrid, 2017.
UN Secretary-General’s High-Level Panel on Access to Medicines Report, 14 September 2016.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License